Vivani Medical (NASDAQ:VANI) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Key Points

• Vivani Medical reported a quarterly loss of $0.07 per share, beating analysts’ estimate of a $0.08 loss by $0.01.
• Shares fell 2.2% to $1.34 following the results. Analysts’ average rating is “Hold”, with an average price target of $3.75.
• Director Gregg Williams purchased approximately 1.59 million shares for $2 million, while company insiders collectively own 53.3% of the stock.

Vivani Medical (NASDAQ:VANI - Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.07) earnings per share for the quarter, topping analysts' consensus estimates of ($0.08) by $0.01, FiscalAI reports.

Vivani Medical Stock Down 2.2%

VANI stock traded down $0.03 during trading on Thursday, reaching $1.34. 195,735 shares of the company's stock were exchanged, compared to its average volume of 364,333. Vivani Medical has a 1-year low of $0.92 and a 1-year high of $1.92. The firm has a market cap of $115.55 million, a PE ratio of -3.35 and a beta of 2.35. The company's fifty day moving average price is $1.29 and its 200-day moving average price is $1.25.

Analyst Upgrades and Downgrades

VANI has been the subject of a number of analyst reports. Weiss Ratings raised shares of Vivani Medical from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Tuesday, July 7th. Lake Street Capital began coverage on Vivani Medical in a report on Tuesday, June 23rd. They set a "buy" rating and a $4.00 price target on the stock. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $3.75.

Insider Activity at Vivani Medical

In related news, Director Gregg Williams acquired 1,587,301 shares of the business's stock in a transaction that occurred on Monday, June 15th. The shares were acquired at an average cost of $1.26 per share, for a total transaction of $1,999,999.26. Following the completion of the purchase, the director directly owned 36,119,086 shares in the company, valued at $45,510,048.36. This trade represents a 4.60% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 53.30% of the company's stock.

Hedge Funds Weigh In On Vivani Medical

Institutional investors and hedge funds have recently bought and sold shares of the stock. Citadel Advisors LLC bought a new stake in shares of Vivani Medical during the 3rd quarter worth about $26,000. Susquehanna International Group LLP lifted its stake in shares of Vivani Medical by 100.5% in the 3rd quarter. Susquehanna International Group LLP now owns 32,314 shares of the company's stock worth $46,000 after acquiring an additional 16,200 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Vivani Medical by 29.6% in the fourth quarter. Geode Capital Management LLC now owns 461,652 shares of the company's stock valued at $568,000 after acquiring an additional 105,398 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Vivani Medical by 118.4% in the fourth quarter. Renaissance Technologies LLC now owns 97,985 shares of the company's stock valued at $121,000 after acquiring an additional 53,127 shares in the last quarter. Finally, Jane Street Group LLC acquired a new position in shares of Vivani Medical during the fourth quarter valued at approximately $60,000. Institutional investors own 6.78% of the company's stock.

Vivani Medical Company Profile

Vivani Medical Solutions, Inc NASDAQ: VANI is a medical technology company focused on the design, development and commercialization of advanced specimen retrieval and hemostasis products for minimally invasive diagnostic procedures. Its core mission is to enhance procedural safety and streamline clinical workflows for interventional radiologists and pathology laboratories.

The company's flagship offerings include the StopBleed Retrieval Device and StopBleed Pad, which integrate proprietary hemostatic materials to control bleeding at biopsy sites and preserve tissue integrity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source